On March 2, 2026, Roche announced that its third and final pivotal Phase III trial of fenebrutinib in multiple sclerosis met its primary endpoint. That means all 3 major studies in the fenebrutinib program (FENhance 1, FENhance 2, and FENtrepid) have now produced positive results. According to the National MS Society, nearly 1 million people living with MS in the United States and 2.9 million worldwide could benefit from developments like these, making this one of the most significant clinical advances in years.
What Is Fenebrutinib, in Plain English?
Multiple sclerosis happens when the immune system mistakenly attacks the protective coating around nerve fibers in the brain and spinal cord. Over time, this damages the nerves themselves, leading to problems with movement, balance, vision, and thinking. There are 2 main ways this damage happens:
Most current MS drugs target only the first problem. They calm down the immune system to reduce relapses, but they do not get inside the brain to address the chronic smoldering damage that drives long-term disability, especially in progressive forms of the disease.
Fenebrutinib is different. It is a BTK inhibitor, meaning it blocks an enzyme called Bruton's tyrosine kinase that both B cells and microglia need to cause damage. Because fenebrutinib can cross the blood-brain barrier, it reaches the microglia inside the brain directly. That dual action on both inflammation and chronic brain damage is what makes it potentially first-in-class.
It is also a pill, taken twice daily. Many of the most effective MS treatments right now require IV infusions at a clinic every few months. An oral drug with this level of efficacy would be a meaningful quality-of-life improvement for many patients.
Fenebrutinib Phase 3 Trial Results for [Multiple Sclerosis](/trials/multiple-sclerosis)
3 Phase III trials, 2,482 patients, all 3 positive
The FENhance 1 and FENhance 2 trials tested fenebrutinib head-to-head against teriflunomide (a widely used oral MS drug) in 1,497 adults with relapsing MS. Both trials ran for at least 96 weeks. According to Genentech's FENhance trial results, the data was consistent across both studies:
Both studies also showed statistically significant reductions in brain lesions on MRI, and all disability progression endpoints trended in fenebrutinib's favor. Full data will be presented at the American Academy of Neurology (AAN) Annual Meeting in 2026.
The FENtrepid trial tested fenebrutinib against Ocrevus (ocrelizumab), which is currently the only approved treatment for primary progressive MS, in 985 patients over at least 120 weeks. According to the FENtrepid trial data, fenebrutinib was non-inferior to Ocrevus in delaying disability progression, and showed a 12% reduction in the risk of disability progression compared to Ocrevus, with the benefit appearing as early as week 24.
Fenebrutinib Safety Profile and Side Effects
No drug is without risks, and transparency matters. The fenebrutinib trials reported some safety signals that deserve attention.
According to the FENhance trial reports, 8 fatal cases occurred in the fenebrutinib arms compared to 1 in the teriflunomide arm. The causes varied and occurred at different points during treatment. Further analyses are ongoing. In the FENtrepid study, the fatality rate was 1.4% in the fenebrutinib arm versus 0.2% in the Ocrevus arm; investigators assessed all cases as unrelated to treatment. Epidemiological research has established that people with MS already face higher mortality rates than the general population, but these numbers will be scrutinized closely.
On liver safety, there was 1 Hy's Law case (a marker for potential drug-induced liver injury) in the fenebrutinib arm and 1 in the teriflunomide arm of FENhance 1. Both were asymptomatic and resolved after stopping the drug. The FDA had previously placed a partial clinical hold on the program in late 2023 after 2 cases of elevated liver enzymes, but that hold was lifted and the trials continued.
These findings will be part of the regulatory review when Roche submits the data to the FDA and other authorities. For patients considering future treatment options, these are important conversations to have with a neurologist.
Why BTK Inhibitors Matter for MS Patients
MS treatment has come a long way over the past 2 decades. There are now more than 20 FDA-approved therapies for relapsing MS. But the treatment landscape has 2 major gaps that fenebrutinib could help fill.
The first is the lack of high-efficacy oral options. The most effective MS drugs currently available, like Ocrevus and Kesimpta, require injections or infusions. Many oral drugs exist, but they tend to be less potent. An oral pill that delivers high efficacy would simplify treatment for a lot of people.
The second is progressive MS. For patients with primary progressive MS, Ocrevus has been the only option since 2017. And for the broader population of people whose MS is transitioning from relapsing to progressive, treatment options narrow significantly. Fenebrutinib's ability to cross the blood-brain barrier and target the chronic inflammation behind progression is exactly the kind of mechanism the field has been looking for.
Roche has said it will submit the totality of data from all 3 Phase III studies to regulatory authorities. If approved, fenebrutinib would represent a fundamentally new approach to treating MS, targeting the disease from both outside and inside the brain with a single oral medication.
Quick Reference: MS by the Numbers
MS is most commonly diagnosed between ages 20 and 40, making it one of the leading causes of neurological disability in young adults. According to MS epidemiological data, about 10-15% of people with MS are diagnosed with the primary progressive form, which involves a steady worsening of symptoms from the start rather than the relapse-remission pattern.